31 results on '"Hruba, Veronika"'
Search Results
2. Subcutaneous Infliximab in Refractory Crohn's Disease Patients: A Possible Biobetter?
3. EFFICIENCY OF DUAL THERAPY WITH VEDOLIZUMAB AND TOFACITINIB IN REFRACTORY ULCERATIVE COLITIS PATIENTS – SINGLE CENTRE EXPERIENCE
4. SUBCUTANEOUS INFLIXIMAB IN REFRACTORY CROHN'S DISEASE PATIENTS AFTER THE MULTIPLE TREATMENT FAILURES - SHORT TREATMENT OUTCOMES
5. Cellular and Humoral Immune Responses to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease Patients
6. DUAL BIOLOGICAL OR SMALL MOLECULE TREATMENT IN INFLAMMATORY BOWEL DISEASES: DATA FROM CLINICAL PRACTICE
7. ANTI-SARS-COV-2 VACCINATION AND ANTIBODY RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON IMMUNE-MODIFYING THERAPY. PROSPECTIVE SINGLE TERTIARY CENTER STUDY ON 602 IBD PATIENTS
8. Dapagliflozin Added to Glimepiride in Patients with Type 2 Diabetes Mellitus Sustains Glycemic Control and Weight Loss Over 48 Weeks: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial
9. Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study
10. Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study.
11. Mo1919 – Ustekinumab Efficiency As a Higher-Line Therapy in Association with Serum Levels in Patients with Crohn’s Disease
12. Mo1894 – Early Vedolizumab Trough Levels are Not Associated with a Short-Term Response in Patients with Inflammatory Bowel Disease
13. Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease
14. Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis – results from multicenter observational cohort
15. Safety of Anti-TNF-Alpha Therapy During Pregnancy on Long-term Outcome of Exposed Children: A Controlled, Multicenter Observation
16. Sa1698 - Impact of Anti-Tnfa Exposure During Pregnancy for Maternal Inflammatory Bowel Disease on Serologic Response to Vaccination of Exposed Children
17. Sa1681 - Anti-Tnfa Exposure During Pregnancy is not Associated with Increased Infection Risk in Exposed Children During the first Year of Life
18. Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort
19. Biosimilar Infliximab in Anti-TNF Naive IBD Patients and One-Year Clinical Follow-Up
20. Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis
21. Sa1957 Switching of Patients With Inflammatory Bowel Disease From Original Infliximab (Remicade®) to Biosimilar Infliximab (Remsima™) Is Effective and Safe
22. 515 Biosimilar Infliximab Is Effective and Safe in Inflammatory Bowel Disease Patients Naïve to Anti-TNF Therapy: A Tertiary Center Experience
23. Sa1958 No Difference in Immunogenicity of the Original and Biosimilar Infliximab in Patients With Inflammatory Bowel Disease: Short-Term Results
24. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation
25. 283 Deep Remission in Crohn's Disease Does Not Prevent Disease Relapse After Withdrawal of Anti-TNFa Therapy
26. Sa1935 - Biosimilar Infliximab in Anti-TNF Naive IBD Patients and One-Year Clinical Follow-Up
27. Sa1206 Risk of Short-Term Endoscopic Recurrence of Crohn's Disease After Ileo-Colonic Resection: Results From a Single, Tertiary IBD Center
28. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
29. ANTI-SARS-COV-2 VACCINATION AND ANTIBODY RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON IMMUNE-MODIFYING THERAPY. PROSPECTIVE SINGLE TERTIARY CENTER STUDY ON 602 IBD PATIENTS.
30. DUAL BIOLOGICAL OR SMALL MOLECULE TREATMENT IN INFLAMMATORY BOWEL DISEASES: DATA FROM CLINICAL PRACTICE.
31. Early vedolizumab trough levels are not associated with a short-term response in patients with inflammatory bowel disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.